Pereira C, Sousa H, Ferreira P, Fragoso M, Moreira-Dias L, Lopes C, Medeiros R, Dinis-Ribeiro M. -765G > C COX-2 polymorphism may be a susceptibility marker for gastric adenocarcinoma in patients with atrophy or intestinal metaplasia. World J Gastroenterol 2006; 12(34): 5473-5478 [PMID: 17006983 DOI: 10.3748/wjg.v12.i34.5473]
Corresponding Author of This Article
Mário Dinis-Ribeiro, MD, PhD, Serviço de Gastrenterologia, Instituto Português de Oncologia do Porto FG EPE, Rua Dr. António Bernardino Almeida, 4200-072 Porto, Portugal. mario@med.up.pt
Article-Type of This Article
Gastric Cancer
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Sep 14, 2006; 12(34): 5473-5478 Published online Sep 14, 2006. doi: 10.3748/wjg.v12.i34.5473
-765G > C COX-2 polymorphism may be a susceptibility marker for gastric adenocarcinoma in patients with atrophy or intestinal metaplasia
Carina Pereira, Hugo Sousa, Paula Ferreira, Maria Fragoso, Luís Moreira-Dias, Carlos Lopes, Rui Medeiros, Mário Dinis-Ribeiro
Carina Pereira, Paula Ferreira, Molecular Oncology Group, Portuguese Institute of Oncology of Porto, Portugal
Maria Fragoso, Oncology Department, Portuguese Institute of Oncology of Porto, Portugal
Luís Moreira-Dias, Gastroenterology Department, Portuguese Institute of Oncology of Porto, Portugal
Hugo Sousa, Carlos Lopes, Rui Medeiros, Molecular Oncology Group, Portuguese Institute of Oncology of Porto, Portugal; and ICBAS, Abel Salazar Institute for the Biomedical Sciences, Porto, Portugal
Mário Dinis-Ribeiro, Gastroenterology Department, Portuguese Institute of Oncology of Porto, Portugal; and Cintesis / Faculty of Medicine University of Porto, Porto, Portugal
Supported by the Portuguese League Against Cancer (Liga Portuguesa Contra o Cancro-Núcleo Regional do Norte) and AstraZeneca Foundation
Correspondence to: Mário Dinis-Ribeiro, MD, PhD, Serviço de Gastrenterologia, Instituto Português de Oncologia do Porto FG EPE, Rua Dr. António Bernardino Almeida, 4200-072 Porto, Portugal. mario@med.up.pt
Received: May 12, 2006 Revised: May 28, 2006 Accepted: June 16, 2006 Published online: September 14, 2006
Abstract
AIM: To investigate the relationship between the -765G > C COX-2 polymorphism and the development of different gastric lesions: atrophy or intestinal metaplasia and gastric adenocarcinoma.
METHODS: A cross-sectional study was performed involving 320 Portuguese individuals (210 without evidence of neoplastic disease, 73 patients with gastric adenocarcinomas and 37 with atrophy or intestinal metaplasia) using a PCR-RFLP method.
RESULTS: -765C allele was overrepresented in the patients with gastric adenocarcinoma (51%) when compared either with the control group (38%) or patients with atrophy or intestinal metaplasia (27%). Callele was found to be very common in our population (0.22), and a multivariate logistic regression analysis revealed nearly 3-fold increased risk for the progression to gastric adenocarcinoma in patients with atrophy or intestinal metaplasia carrying the -765C allele (OR = 2.67, 95% CI = 1.03-6.93; P = 0.04).
CONCLUSION: -765C carrier status should be considered as another susceptibility marker for gastric adenocarcinoma development in patients with atrophy or intestinal metaplasia.
